Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects

被引:55
|
作者
Bonadonna, S
Burattin, A
Nuzzo, M
Bugari, G
Rosei, EA
Valle, D
Iori, N
Bilezikian, JP
Veldhuis, JD
Giustina, A
机构
[1] Univ Brescia, Dept Med Sci, Brescia, Italy
[2] Spedali Civil Brescia, Lab 3, Brescia, Italy
[3] Eli Lilly & Co, Div Med, Florence, Italy
[4] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA
[5] Mayo Clin, Rochester, MN USA
关键词
D O I
10.1530/eje.1.01841
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Spontaneous parathyroid hormone (PTH) secretory dynamics include tonic and pulsatile components. It is not known how glucocorticoids might alter these secretory dynamics. Design: The aim of our study was to evaluate spontaneous fluctuations in serum PTH levels in six adult male patients (aged 31 - 64 years) receiving chronic ( > 6 months) therapy with glucocorticoids (daily dosage > 7.5 mg of prednisone or dose equivalent of other corticosteroid) as compared with a control group of 10 age- and sex-matched normal subjects. Methods: Peripheral venous blood. sampling was performed every 3 min for 6 h from 0900 to 1500 h. Plasma PTH release profiles were subjected to deconvolution analysis, a method that resolves measured hormone concentrations into secretion and clearance components, and to an approximate entropy (ApEn) estimate, that in turn provides an integrated measure of the serial regularity or orderliness of the release process. Results: In the glucocorticoid-treated group, the PTH tonic secretory rate was reduced (4.3+/-0.74 vs 8.8 +/- 1.4 pg/ml per min in controls, P = 0.017). There was, however, an increase in the fractional pulsatile PTH secretion (42+/-8.2 vs 18.3 +/- 3.9 pg/ml per min, P = 0.006) in glucocorticoid-treated vs normal subjects. Mean overall PTH concentration, as well as mean integrated area, was similar among normal and glucocorticoid-treated subjects. Conclusions: These results demonstrate, for the first time, that chronic glucocorticoid treatment induces a redistribution of spontaneous PTH secretory dynamics by reducing the amount released in tonic fashion and increasing the amount released as pulses.
引用
收藏
页码:199 / 205
页数:7
相关论文
共 50 条
  • [31] The use of intermittent human parathyroid hormone as a treatment for osteoporosis.
    Deal C.
    Current Rheumatology Reports, 2004, 6 (1) : 49 - 58
  • [32] Simple approach to reducing proteolysis during secretory production of human parathyroid hormone in Saccharomyces cerevisiae
    Chung, BH
    Park, KS
    BIOTECHNOLOGY AND BIOENGINEERING, 1998, 57 (02) : 245 - 249
  • [33] Recombinant human parathyroid hormone - Osteoporosis is proving amenable to treatment
    Reeve, J
    BRITISH MEDICAL JOURNAL, 2002, 324 (7335): : 435 - 436
  • [34] RESTORATION OF PHOSPHATURIC RESPONSE TO PARATHYROID-HORMONE BY GLUCOCORTICOID TREATMENT IN PHOSPHORUS-DEPRIVED RATS
    CZEKALSKI, S
    KNOX, FG
    DOUSA, TP
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1982, 100 (06): : 858 - 865
  • [35] REGULATION OF THE HUMAN GLUCOCORTICOID RECEPTOR BY LONG-TERM AND CHRONIC TREATMENT WITH GLUCOCORTICOID
    SILVA, CM
    POWELLOLIVER, FE
    JEWELL, CM
    SAR, M
    ALLGOOD, VE
    CIDLOWSKI, JA
    STEROIDS, 1994, 59 (07) : 436 - 442
  • [36] SINGLE DOSE AND PULSATILE TREATMENT WITH HUMAN GROWTH-HORMONE IN GROWTH-HORMONE DEFICIENCY
    SMITH, PJ
    PRINGLE, PJ
    BROOK, CGD
    ARCHIVES OF DISEASE IN CHILDHOOD, 1987, 62 (08) : 849 - 851
  • [37] Parathyroid hormone treatment reverses glucocorticoid-induced osteoporosis: Results of a randomized controlled trial.
    Lane, NE
    Roe, B
    Genant, HK
    Arnaud, C
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 1757 - 1757
  • [38] EFFECT OF THE COMBINED ADMINISTRATION OF GALANIN AND CLONIDINE ON SERUM GROWTH-HORMONE LEVELS IN NORMAL SUBJECTS AND IN PATIENTS UNDER CHRONIC GLUCOCORTICOID TREATMENT
    GIUSTINA, A
    BOSSONI, S
    LICINI, M
    MACCA, C
    MILANI, G
    WEHRENBERG, WB
    ENDOCRINE RESEARCH, 1994, 20 (02) : 151 - 164
  • [39] Parathyroid hormone treatment of women with glucocorticoid-induced osteoporosis dramatically increases bone turnover.
    Lane, NE
    Thompson, JM
    Modin, G
    Pierini, E
    Sanchez, S
    Arnaud, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 : 109 - 109
  • [40] Treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone and electromagnetic field
    Xuan, Miao
    Wang, Bo
    Bi, Wanrong
    Li, Ying
    Song, Lige
    Xie, Zhuangli
    Liu, Qi
    Zhang, Xiuzhen
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2025, 37 (01)